Eli Lilly reported that the results of ANNOUNCE, the Phase III study of Lartruvo (olaratumab), in combination with doxorubicin in...
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination on Lartruvo (olaratumab), from Eli...
The FDA has granted accelerated approval to Lartruvo (olaratumab), from Eli Lilly, with doxorubicin to treat adults with certain types...
The European Commission has granted an accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin as a frontline therapy for...